Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409203 | 0.87 | PIK3CA (0.57) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL1409215 | 0.86 | PIK3CA (0.54) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL1409412 | 0.81 | ADORA2A (0.37) | PIK3CAMTORADORA2AHDAC4HDAC6 | |
| SCHEMBL18660598 | 0.79 | PIK3CA (0.57) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL1409236 | 0.79 | MTOR (0.47) | PIK3CAMTORADORA2APIK3R1 | |
| SCHEMBL32208 | 0.75 | MTOR (0.64) | PIK3CAMTORPIK3CGPIK3R1 | |
| SCHEMBL1409540 | 0.74 | PIK3CA (0.54) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL32267 | 0.74 | MTOR (0.64) | PIK3CAMTORPIK3CGPIK3R1 | |
| SCHEMBL1408711 | 0.74 | MTOR (0.58) | PIK3CAMTORPIK3R1 | |
| SCHEMBL1409222 | 0.73 | MTOR (0.56) | PIK3CAMTORPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216793-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3216793-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2294072-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9174963-B2 | Triazine compounds as PI3 kinase and MTOR inhibitors | PFIZER INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2015-01-08 | — | — | US | disclosed |
| US-8859542-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2300483-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2294072-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143317-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | PIK3CA 2/4885MTOR 1/4885PIK3CG 18/4885 |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | PIK3CA 2/4885MTOR 1/4885PIK3CG 18/4885 |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CG 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.